CD16xCD33 bispecific killer cell engager (BiKE) activates natural killer (NK) cells from myelodysplastic syndrome (MDS) patients against primary MDS and myeloidderived suppressor cell (MDSC) CD33-positive targets
Year: 2014
Type: dissertation
Abstract: University of Minnesota M.S. thesis. November 2014. Major: Clinical Research. Advisor: Julie A. Ross, PhD, MPH. 1 computer file (PDF); vii, 41 pages, appendices p. 32-41.
Author: Michelle Gleason
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, University of Minnesota, Center for Evolutionary and Theoretical Immunology, National Institutes of Health, Health Resources and Services Administration, U.S. Navy, Masonic Cancer Center, University of Minnesota, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G1072197786, G1585145239, G2220088171, G3070582560, G317906537, Predictors of Myelodysplastic Syndrome in Minnesota, G3609734018, Established Investigator Award in Pediatric Cancer Epidemiology, G4928541993, G541973719, G5569911400, G5699415455, DEVELOPMENT OF MEDICAL TECHNOLOGY FOR CONTINGENCY RESPONSE TO MARROW TOXIC SUBSTANCE, G5950000589, G6749775408, BMT Clinical Research Network Data Coordinating Center, G7160503914, G7685818843, G8107732965, G8464307619, G8876996369, G894505544, Translational and genomic pediatric cancer epidemiology training program, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Cancer Center Support Grant, NK cells, their receptors and cancer therapy, G909763084
OpenAlex ID: W2262441481